Panitumumab-Induced Eruptive Seborrhoeic Keratosis in a Patient with Metastatic Colorectal Cancer

  • Dimitra Koumaki Dermatology Department, University Hospital of Heraklion, PAGNI, Heraklion, Crete, Greece
  • Sotirios Boumpoucheropoulos Medical Oncology Department, Agii Anargiri General Oncological Hospital of Kifisia, Athens, Greec
  • Vasiliki Koumaki Department of Microbiology, Medical School of Athens, Greece
  • Alexander Katoulis Department of Dermatology, Attikon University Hospital, Athens, Greece
  • Georgia Pappas Medical Oncology Department, Agii Anargiri General Oncological Hospital of Kifisia, Athens, Greece
  • Aikaterini Mantaka Department of Gastroenterology, University Hospital of Heraklion, PAGNI, Heraklion, Crete, Greece
  • Konstantinos Krasagakis Dermatology Department, University Hospital of Heraklion, PAGNI, Heraklion, Crete, Greece

Keywords

Panitumumab, eruptive seborrhoeic keratosis, drug-induced eruption

Abstract

Objectives: Agents targeting the epidermal growth factor receptor (EGFR)-mediated signalling pathway are increasingly being used for the treatment of advanced lung, pancreatic, colorectal and head and neck cancers.
Case presentation: Here, we report the first case of eruptive seborrhoeic keratosis following panitumumab treatment, an anti-EGFR monoclonal antibody, in a 73-year-old patient with stage 4 (IV) colorectal cancer with hepatic metastasis.
Conclusion: While panitumumab is an emerging therapy for RAS wild-type metastatic colorectal cancer, physicians should consider panitumumab as a potential cause of eruptive seborrhoeic keratosis.

VIEW THE ENTIRE ARTICLE

References

  • Stremitzer S, Sebio A, Stintzing S, Lenz HJ. Panitumumab safety for treating colorectal cancer. Expert Opin Drug Saf 2014;13:843–851.

  • Nanney LB, Stoscheck CM, King LE Jr, Underwood RA, Holbrook KA.Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990;94742–748.

  • Guttman-Yassky E, Mita A, De Jonge M, Matthews L, McCarthy S, Iwata KK, et al. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 2010;46:2010–2019.

  • Fink AM, Filz D, Krajnik G, Jurecka W, Ludwig H, Steiner A. Seborrhoeic kerato¬ses in patients with internal malignancies: a case-control study with prospective accrual of patients. J Eur Acad Dermatol Venereol 2009;23:1316–1319.

  • Lilly E, Granter SR, Haynes HA, Ibrahimi OA. Chemotherapy-induced inflammatory seborrheic keratoses in a man with acute myeloid leukemia: a variant of Leser-Trélat sign? Cutis 2012;90:235–236.
  • Published: 2020-01-15

    Issue: Vol 7 No 2 (view)

    Section: Articles

    How to cite:
    1.
    Koumaki D, Boumpoucheropoulos S, Koumaki V, Katoulis A, Pappas G, Mantaka A, Krasagakis K. Panitumumab-Induced Eruptive Seborrhoeic Keratosis in a Patient with Metastatic Colorectal Cancer. EJCRIM [Internet]. 2020Jan.15 [cited 2020Sep.18];7(2). Available from: https://ejcrim.com/index.php/EJCRIM/article/view/1411

    Most read articles by the same author(s)